Is Barnwell Industries, Inc. (NYSEAMERICAN:BRN) Stock a Buy after James Barnwell’s Insider Purchase?; Alkermes (ALKS)’s Sentiment Is 0.75

James Barnwell; that is an insider in Barnwell Industries Inc who is the latest to buy shares in the company for which he is right now a director. He recently obtained 2,500 shares of the company, with value $4,875 U.S Dollars, that is a price per share of approximately $2.0. And, It’s sure James’s transaction isn’t going to remain hidden as he currently is holding 28,726 shares – ( 0.35% of Barnwell Industries Inc’s Market Cap ).

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $9.60 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Meditor Group Ltd holds 7.95% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 48,244 shares or 2.2% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 1.64% invested in the company for 68,621 shares. The California-based Kelly Lawrence W & Associates Inc Ca has invested 1.24% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 40,000 shares.

Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 13.82% above today’s ($61.5) share price. ALKS was included in 3 notes of analysts from October 21, 2016. Jefferies maintained the shares of ALKS in report on Friday, October 21 with “Buy” rating. The rating was upgraded by JP Morgan on Friday, October 21 to “Overweight”. The firm has “Outperform” rating by Leerink Swann given on Friday, October 21.

The stock increased 1.91% or $1.15 during the last trading session, reaching $61.5. About 537,904 shares traded. Alkermes plc (ALKS) has risen 47.50% since March 15, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.

Investors sentiment increased to 2 in Q3 2017. Its up 1.67, from 0.33 in 2017Q2. It improved, as 3 investors sold Barnwell Industries, Inc. shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 890,915 shares or 19.81% less from 1.11 million shares in 2017Q2 were reported. Florida-based Raymond James & has invested 0% in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). The Pennsylvania-based Vanguard has invested 0% in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). Lsv Asset Mgmt invested 0% of its portfolio in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). Northern Trust accumulated 16,404 shares or 0% of the stock. Dimensional Fund Advsr Limited Partnership owns 434,210 shares. Renaissance Technologies Lc holds 0% or 91,700 shares. Acadian Asset Management Ltd Liability reported 9,526 shares or 0% of all its holdings. Bancorp Of America Corp De invested 0% in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). Geode Management Limited Liability Corporation invested 0% of its portfolio in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). California Public Employees Retirement System holds 25,200 shares. Comml Bank Of New York Mellon reported 0% in Barnwell Industries, Inc. (NYSEAMERICAN:BRN). Blackrock holds 0% of its portfolio in Barnwell Industries, Inc. (NYSEAMERICAN:BRN) for 86,692 shares.

Since January 12, 2018, it had 2 insider buys, and 0 selling transactions for $8,782 activity. Shares for $4,364 were bought by KINZLER ALEXANDER C on Thursday, February 15. On Friday, January 12 Gardner Murray C bought $4,418 worth of Barnwell Industries, Inc. (NYSEAMERICAN:BRN) or 2,000 shares.

Barnwell Industries, Inc., through its subsidiaries, acquires, develops, produces, and sells oil and natural gas in Canada. The company has market cap of $16.14 million. The firm operates through three divisions: Oil and Natural Gas, Land Investment, and Contract Drilling. It currently has negative earnings. It holds working interests in oil and natural gas properties located in Alberta, Saskatchewan, and British Columbia.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter:



 

Recent Posts